A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
The reaction proceeds in three oxidations, each catalysed by the enzyme, which is a cytochrome P450 protein containing heme, isolated from Artemisia annua. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. The product is used by the plant in the biosynthesis of artemisinin.
=== Pharmacokinetics === KNX-100 has improved pharmacokinetics relative to oxytocin, such as enhanced oral bioavailability, blood–brain barrier permeability, and metabolic stability, and may overcome the pharmacokinetic and efficacy limitations of oxytocin.
== Mental health == The high rate of smoking tobacco by people with mental health problems is a major factor in their decreased life expectancy, which is about 25 years shorter than that of the general population.
== Potential drug targets == In the treatment of epilepsy, drugs such as vigabatrin that target both GABA transporters and the GABA metabolizing enzyme GABA-transaminase have been marketed, providing proof of principle for the neurotransmitter cycling systems as pharmacological targets. However, with regard to glutamate transport and metabolism, no such drugs have been developed, because glutamatergic synapses are abundant, and the neurotransmitter glutamate is an important metabolite in metabolism, making interference capable of adverse effects. So far, most of the drug development directed at the glutamatergic system seems to have been focused on ionotropic glutamate receptors as pharmacological targets, although G-protein coupled receptors have been attracting increased attention over the years.
Sources: en.wikipedia.org
A survival store is a retail outlet where outdoor survival or preparedness equipment can be purchased. Typically survival stores stock camping and backpacking equipment, long-term storage food, fishing equipment, and occasionally bicycles.
=== Patent === Dow Pharmaceuticals filed the patent for Onexton, and the United States Patent and Trademark Office issued the patent on 16 October 2012. On 24 November 2014, the US Food and Drug Administration (FDA) approved the new drug application (NDA) No. 050819 for Onexton, with Dow Pharmaceutical as the holder. The patent is set to expire on 5 August 2029.
==== UN committee report ==== The United Nations (UN) had set up its own committee, the 'Paul Volcker Committee', to investigate alleged corruption in the Oil-for-Food program. In its October 2005 report, it stated that "over 18 million barrels of oil were allocated either directly in the name of George Galloway ... or in the name of one of his associates, Fawaz Abdullah Zureikat, to support Mr Galloway's campaign against sanctions ... Zureikat received commissions for handling the sale of approximately 11 million barrels that were allocated in Mr Galloway's name". The report further holds that: "Iraq officials identified Mr Zureikat as acting on Mr Galloway's behalf to conduct the oil transactions in Baghdad". The report states that payments of $445,000 were channelled through Galloway's Mariam Appeal, and claims that $120,000 from oil sales was paid into the bank account of Galloway's wife Amineh Abu Zayyad, who was also involved with the Mariam Appeal. The committee chairman, Paul Volcker, suggested that his investigation had further material about Galloway which had not been published. He said "If the legal authorities in Britain want to discuss with us what other evidence we may have, that may not be in the report, then we would be prepared to co-operate". However, the committee did not show evidence that any of the money was paid directly into accounts held by George Galloway. The report acknowledges that "both Mr Galloway and Mr Zureikat have denied that Mr Galloway was involved in obtaining the oil allocations or receiving any proceeds from the oil sales".
Sources: en.wikipedia.org
== Early life, education, and career == Wittman was born in Washington, D.C., the son of adoptive parents Regina C. (née Wood) and Frank Joseph Wittman. His father was of German descent and his mother's ancestors included immigrants from Ireland and Canada. He grew up in Henrico County, Virginia. He attended the Virginia Polytechnic Institute and State University (Virginia Tech) as a member of the Corps of Cadets and Army ROTC and studied biology. While at Virginia Tech, he spent the summers working at a tomato cannery and on a fishing vessel. Also while in college, Wittman was a member of the Delta Tau Delta fraternity. He earned a master's degree in public health from the University of North Carolina at Chapel Hill in 1990 and a Ph.D. from Virginia Commonwealth University in 2002. Wittman worked for 20 years with the Virginia Department of Health. He served as an environmental health specialist and was field director for the Division of Shellfish Sanitation. Wittman served on the Montross Town Council from 1986 to 1996 and as mayor of the Town of Montross from 1992 to 1996. Two of his major initiatives in this office were the overhaul of the sewage system and the development of a computerized system for tax billing. From 1996 to 2005, Wittman served on the Westmoreland County Board of Supervisors, the last two years as chair. He helped create new libraries and pushed for raises in teacher salaries.
While not as life-threatening as a bite from a venomous species, the bite can be at least temporarily debilitating and could lead to dangerous infections if improperly dealt with. While most snakes must open their mouths before biting, African and Middle Eastern snakes belonging to the family Atractaspididae can fold their fangs to the side of their head without opening their mouth and jab a person.
The city was developed on the land of various plantations including Crabtree, Mordecai, Oak View, Pine Hall, Pullen, Spring Hill, and Wakefield. The North Carolina General Assembly first met in Raleigh in December 1794, and granted the city a charter, with a board of seven appointed commissioners and an "Intendant of Police" (which developed as the office of Mayor) to govern it. After 1803, city commissioners were elected. In 1799, the N.C. Minerva and Raleigh Advertiser was the first newspaper published in Raleigh. John Haywood was the first Intendant of Police.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.